Lupin to Launch Bofanglutide in India for Diabetes & Obesity

Lupin Limited has signed an exclusive license, supply, and distribution agreement to commercialize Bofanglutide in India, marking a major step in the battle against type 2 diabetes and obesity.

Under the pact with China’s Gan&Lee Pharmaceuticals, Lupin gains sole rights to sell this novel fortnightly GLP-1 receptor agonist for adults with type 2 diabetes and overweight or obese adults needing weight management.

Bofanglutide stands out by being administered once every two weeks, offering patients a lower injection frequency than existing weekly GLP-1 therapies. Early clinical results show it delivers weight loss and glycemic control on par with or better than current options, while maintaining a safety and tolerability profile consistent with others in the GLP-1 class. This could make long-term treatment simpler for many patients.

Also Read: Advancing Interventional Radiology in India Through Collaboration

The deal strengthens Lupin’s metabolic health portfolio and supports its entry into the fast-growing obesity treatment segment in India. With an estimated 90 million adults living with diabetes and nearly 50 million classified as obese, the company sees strong demand for improved care options. The convenience of a fortnightly dosing schedule may also boost treatment adherence.

Nilesh Gupta, Managing Director of Lupin, said the partnership reflects the company’s commitment to expanding access to innovative therapies for chronic metabolic conditions. Rajeev Sibal, President – India Region Formulations, noted that the reduced injection frequency provides a meaningful advantage while delivering clinically proven outcomes.

Gan&Lee Pharmaceuticals highlighted that this collaboration aligns with its global expansion strategy. The company is a leading insulin manufacturer in China and holds regulatory approvals in multiple markets, including GMP clearance from the European Medicines Agency.